IRIS Accounts Production v25.1.0.734 10921842 Board of Directors 1.5.23 30.4.24 30.4.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh109218422023-04-30109218422024-04-30109218422023-05-012024-04-30109218422022-04-30109218422022-05-012023-04-30109218422023-04-3010921842ns15:EnglandWales2023-05-012024-04-3010921842ns14:PoundSterling2023-05-012024-04-3010921842ns10:Director12023-05-012024-04-3010921842ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3010921842ns10:SmallEntities2023-05-012024-04-3010921842ns10:AuditExempt-NoAccountantsReport2023-05-012024-04-3010921842ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-3010921842ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-3010921842ns10:FullAccounts2023-05-012024-04-301092184212023-05-012024-04-3010921842ns10:Director22023-05-012024-04-3010921842ns10:RegisteredOffice2023-05-012024-04-3010921842ns5:CurrentFinancialInstruments2024-04-3010921842ns5:CurrentFinancialInstruments2023-04-3010921842ns5:Non-currentFinancialInstruments2024-04-3010921842ns5:Non-currentFinancialInstruments2023-04-3010921842ns5:ShareCapital2024-04-3010921842ns5:ShareCapital2023-04-3010921842ns5:RetainedEarningsAccumulatedLosses2024-04-3010921842ns5:RetainedEarningsAccumulatedLosses2023-04-3010921842ns5:LandBuildings2023-05-012024-04-3010921842ns5:PlantMachinery2023-05-012024-04-3010921842ns5:NetGoodwill2023-04-3010921842ns5:NetGoodwill2023-05-012024-04-3010921842ns5:NetGoodwill2024-04-3010921842ns5:NetGoodwill2023-04-3010921842ns5:LandBuildings2023-04-3010921842ns5:PlantMachinery2023-04-3010921842ns5:LandBuildings2024-04-3010921842ns5:PlantMachinery2024-04-3010921842ns5:LandBuildings2023-04-3010921842ns5:PlantMachinery2023-04-3010921842ns5:CostValuation2023-04-3010921842ns5:WithinOneYearns5:CurrentFinancialInstruments2024-04-3010921842ns5:WithinOneYearns5:CurrentFinancialInstruments2023-04-30
REGISTERED NUMBER: 10921842 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 April 2024

for

TCP Pharma Limited

TCP Pharma Limited (Registered number: 10921842)

Contents of the Financial Statements
for the Year Ended 30 April 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


TCP Pharma Limited

Company Information
for the Year Ended 30 April 2024







DIRECTORS: Mr. N Chahal
Mr. D Chahal





REGISTERED OFFICE: Office 1
21 Hatherton Street
Walsall
WS4 2LA





REGISTERED NUMBER: 10921842 (England and Wales)





ACCOUNTANTS: Dhillon Accountants Limited
Chartered Accountants
Office 1
21 Hatherton Street
Walsall
WS4 2LA

TCP Pharma Limited (Registered number: 10921842)

Balance Sheet
30 April 2024

30.4.24 30.4.23
Notes £    £   
FIXED ASSETS
Intangible assets 4 611,765 1,323,149
Tangible assets 5 166,439 202,643
Investments 6 2,194,570 2,194,570
2,972,774 3,720,362

CURRENT ASSETS
Stocks 260,000 322,334
Debtors 7 1,463,339 1,044,091
Cash at bank and in hand 68,469 66,597
1,791,808 1,433,022
CREDITORS
Amounts falling due within one year 8 (2,884,965 ) (3,110,447 )
NET CURRENT LIABILITIES (1,093,157 ) (1,677,425 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,879,617

2,042,937

CREDITORS
Amounts falling due after more than
one year

9

(774,129

)

(858,481

)

PROVISIONS FOR LIABILITIES (41,610 ) (15,931 )
NET ASSETS 1,063,878 1,168,525

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 1,063,778 1,168,425
SHAREHOLDERS' FUNDS 1,063,878 1,168,525

TCP Pharma Limited (Registered number: 10921842)

Balance Sheet - continued
30 April 2024


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 April 2025 and were signed on its behalf by:





Mr. N Chahal - Director


TCP Pharma Limited (Registered number: 10921842)

Notes to the Financial Statements
for the Year Ended 30 April 2024


1. STATUTORY INFORMATION

TCP Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about TCP Pharma Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Land and buildings - 25% on reducing balance
Plant and machinery etc - 25% on reducing balance and 15% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


TCP Pharma Limited (Registered number: 10921842)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 36 (2023 - 16 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 May 2023 1,563,149
Disposals (661,781 )
At 30 April 2024 901,368
AMORTISATION
At 1 May 2023 240,000
Charge for year 49,603
At 30 April 2024 289,603
NET BOOK VALUE
At 30 April 2024 611,765
At 30 April 2023 1,323,149

TCP Pharma Limited (Registered number: 10921842)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024


5. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1 May 2023 13,334 397,138 410,472
Additions - 11,895 11,895
At 30 April 2024 13,334 409,033 422,367
DEPRECIATION
At 1 May 2023 4,482 203,347 207,829
Charge for year 2,213 45,886 48,099
At 30 April 2024 6,695 249,233 255,928
NET BOOK VALUE
At 30 April 2024 6,639 159,800 166,439
At 30 April 2023 8,852 193,791 202,643

6. FIXED ASSET INVESTMENTS
Other
investments
£   
COST
At 1 May 2023
and 30 April 2024 2,194,570
NET BOOK VALUE
At 30 April 2024 2,194,570
At 30 April 2023 2,194,570

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.24 30.4.23
£    £   
Trade debtors 265,404 246,793
Amounts owed by group undertakings 18,342 -
Other debtors 1,179,593 797,298
1,463,339 1,044,091

TCP Pharma Limited (Registered number: 10921842)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024


8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.24 30.4.23
£    £   
Bank loans and overdrafts 143,345 132,725
Trade creditors 689,227 685,825
Taxation and social security 104,189 98,834
Other creditors 1,948,204 2,193,063
2,884,965 3,110,447

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN
ONE YEAR
30.4.24 30.4.23
£    £   
Bank loans 774,129 858,481

10. RELATED PARTY DISCLOSURES

Included in other debtors are the balances due from the companies mentioned below as at 30 April 2024:

- Carters Green WB Properties Limited - £60,100 (2023 - £60,100)
- Carters Green Business Center Limited - £260,341 (2023 - £417,786)
- Pillpharm Limited - £45,049 (2023 - £46,907)
- TCP Huccle Limited - £120 (2023 - Nil)
- Iaesthetics West Brom Limited - £120 (2023 - Nil)
- N&V Transport Limited - £120 (2023 - Nil)
- William Star Limited - £120 (2023 - Nil)
- TCP Partnership Limited - £120 (2023 - Nil)
- Pure Relief Limited - £34,034 (2023 - £25,205)
- Trilogy Pharma Limited - £6,667 (2023 - Nil)
- West Brom Lyng Limited - £678,619 (2023 - Nil)

Included in other creditors are the balances due to the companies mentioned below as at 30
April 2024:

- Ian Mcardle Limited - £36,661 (2023 - £324,226)
- O'Connor Pharmacies Limited - £214,622 (2023 - £348,551)
- TCP Properties Limited - £143,707 (2023 - £102,776 Debit balance)
- West Brom Lodge Limited - £19,811 (2023 - £1,000 Debit balance)

The all above loans are interest free and repayable on demand.

Mr Navdeep Chahal and Mr Dalwinder Chahal are the directors of above mentioned companies as at 30 April 2024.

TCP Pharma Limited (Registered number: 10921842)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024


11. ULTIMATE CONTROLLING PARTY

The company's ultimate controlling party is Mr Navdeep and Mr Dalwinder Chahal by virtue of their ownership of 100% of the issued share capital in the company.